Abbott has received FDA approval for a neuromodulation system-controller app that runs on iOS devices, the company announced Thursday.
Compatible with Abbott's broader NeuroSphere Digital Care platform, the Patient Controller app replaces the separate device patients use to adjust the company's neuromodulation products. These include the Infinity DBS System for Parkinson's disease or essential...
Abbott’s Infinity Deep Brain Stimulation (DBS) system has received an expanded clearance from the FDA that now permits the targeted stimulation of a new area of the brain associated with Parkinson’s disease symptoms.
By now targeting the internal globus pallidus alongside the subthalamic nucleus and ventral intermediate nucleus, the company says that its system “is now the only directional DBS...
Apple's high on health. Apple CEO Tim Cook was pleased as punch with his company’s latest quarterly and yearly report, which he said on an investor’s call yesterday was Apple’s “highest revenue in a September quarter ever” at $64 billion. Thirty-three million dollars of this was in iPhone revenue — a 9% decline over last year that he felt was a significant step up from the 15% decline seen...
Medical tech company Medtronic has just landed FDA clearance on its Deep Brain Stimulation (DBS) Clinical Programmer and ActivaProgramming application.
"This marks a new era of innovation from the only partner with a 25-year DBS legacy, and paves the way to our vision of the future of DBS with a fully integrated system from planning to programming," said Mike Daly, vice president and general...
Parkinson's disease is considered a movement disorder, so it lends itself quite well to mobile technologies. At least one tablet-based device to measure Parkinsonian tremors is already on the market, while an iPhone measurement system passed muster in a clinical trial more than a year ago.
Two weeks ago at the AdvaMed 2011 medical technology conference in Washington, D.C., Great Lakes...
